Arcutis pre-announces Q3 revenue of $38.1M; ZORYVE approved for pediatric psoriasis

Arcutis Biotherapeutics, Inc.

2023-Q3 EPS reported -$3.19 revenue$46,080,000

Preliminary Q3 2023 total revenue of $38.1M: $8.1M net product revenue (ZORYVE) and $30M other revenue from Huadong Medicine license.
Cash, equivalents, and marketable securities of $228.1M as of Sep 30, 2023.
FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis in children ages 6-11, including intertriginous areas.
Positive topline data from INTEGUMENT-PED and INTEGUMENT-OLE trials for atopic dermatitis in pediatric patients.
Company implemented headcount reductions to align with pipeline reprioritization and improve financial flexibility.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported three months ended September 30, 2023 results: revenue total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and oth.

Period: three months ended September 30, 2023
Revenue: total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and oth
Result: preliminary results

Exact text from the filing

While the Company has not finalized its full financial results as of and for the quarter ended September 30, 2023, the Company expects to report that for the three months ended September 30, 2023, the Company generated total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and other revenue of $30.0 million.

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-034688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.